Next Article in Journal
Febrile Seizures and Measles-Containing Vaccines in China: A Self-Controlled Case Series Study
Next Article in Special Issue
The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis
Previous Article in Journal
Worldwide Vaccination Willingness for COVID-19: A Systematic Review and Meta-Analysis
Review

Plasmodium falciparum Malaria Vaccines and Vaccine Adjuvants

1
Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Université de Paris, F-75006 Paris, France
2
A*STAR Infectious Diseases Labs, 8A Biomedical Grove, Singapore 138648, Singapore
3
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore
4
School of Biological Sciences, Nanyang Technological University, Singapore 308232, Singapore
5
Vaccine Immunology Laboratory, Organic Synthesis and Process Chemistry Division, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India
6
Biological Sciences & Engineering, Indian Institute of Technology Palakkad, Palakkad 678623, India
*
Authors to whom correspondence should be addressed.
Equally contributed.
Academic Editor: Giampiero Girolomoni
Vaccines 2021, 9(10), 1072; https://doi.org/10.3390/vaccines9101072
Received: 14 August 2021 / Revised: 10 September 2021 / Accepted: 22 September 2021 / Published: 24 September 2021
Malaria—a parasite vector-borne disease—is a global health problem, and Plasmodium falciparum has proven to be the deadliest among Plasmodium spp., which causes malaria in humans. Symptoms of the disease range from mild fever and shivering to hemolytic anemia and neurological dysfunctions. The spread of drug resistance and the absence of effective vaccines has made malaria disease an ever-emerging problem. Although progress has been made in understanding the host response to the parasite, various aspects of its biology in its mammalian host are still unclear. In this context, there is a pressing demand for the development of effective preventive and therapeutic strategies, including new drugs and novel adjuvanted vaccines that elicit protective immunity. The present article provides an overview of the current knowledge of anti-malarial immunity against P. falciparum and different options of vaccine candidates in development. A special emphasis has been made on the mechanism of action of clinically used vaccine adjuvants. View Full-Text
Keywords: anti-malarial drugs; malaria vaccine; Plasmodium falciparum; vaccine adjuvants anti-malarial drugs; malaria vaccine; Plasmodium falciparum; vaccine adjuvants
Show Figures

Figure 1

MDPI and ACS Style

Bonam, S.R.; Rénia, L.; Tadepalli, G.; Bayry, J.; Kumar, H.M.S. Plasmodium falciparum Malaria Vaccines and Vaccine Adjuvants. Vaccines 2021, 9, 1072. https://doi.org/10.3390/vaccines9101072

AMA Style

Bonam SR, Rénia L, Tadepalli G, Bayry J, Kumar HMS. Plasmodium falciparum Malaria Vaccines and Vaccine Adjuvants. Vaccines. 2021; 9(10):1072. https://doi.org/10.3390/vaccines9101072

Chicago/Turabian Style

Bonam, Srinivasa R., Laurent Rénia, Ganesh Tadepalli, Jagadeesh Bayry, and Halmuthur M.S. Kumar 2021. "Plasmodium falciparum Malaria Vaccines and Vaccine Adjuvants" Vaccines 9, no. 10: 1072. https://doi.org/10.3390/vaccines9101072

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop